WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant
- PMID: 8266105
- DOI: 10.1126/science.8266105
WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant
Abstract
A human Wilms tumor cell line (RM1) was developed to test the tumor suppressor activity of WT1, a zinc finger transcription factor that is expressed in the developing human kidney and is mutationally inactivated in a subset of Wilms tumors. Transfection of each of four wild-type WT1 isoforms suppressed the growth of RM1 cells. The endogenous WT1 transcript in these cells was devoid of exon 2 sequences, a splicing alteration that was also detected in varying amounts in all Wilms tumors tested but not in normal kidney. Production of this abnormal transcript, which encodes a functionally altered protein, may represent a distinct mechanism for inactivating WT1 in Wilms tumors.
Similar articles
-
Differentially spliced exon 5 of the Wilms' tumor gene WT1 modifies gene function.Anticancer Res. 1996 Mar-Apr;16(2):621-6. Anticancer Res. 1996. PMID: 8687106
-
EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.Oncogene. 2000 Feb 10;19(6):791-800. doi: 10.1038/sj.onc.1203390. Oncogene. 2000. PMID: 10698497
-
Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells.Oncogene. 1996 Feb 1;12(3):537-46. Oncogene. 1996. PMID: 8637710
-
Wilms tumor and the WT1 gene.Exp Cell Res. 2001 Mar 10;264(1):74-99. doi: 10.1006/excr.2000.5131. Exp Cell Res. 2001. PMID: 11237525 Review.
-
The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor.FASEB J. 1993 Jul;7(10):896-903. FASEB J. 1993. PMID: 8393820 Review.
Cited by
-
Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies.Front Immunol. 2015 Feb 4;6:36. doi: 10.3389/fimmu.2015.00036. eCollection 2015. Front Immunol. 2015. PMID: 25699052 Free PMC article. Review.
-
Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers.Pharmaceutics. 2018 May 26;10(2):65. doi: 10.3390/pharmaceutics10020065. Pharmaceutics. 2018. PMID: 29861465 Free PMC article. Review.
-
Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression.Mol Cell Biol. 1995 Jul;15(7):3516-22. doi: 10.1128/MCB.15.7.3516. Mol Cell Biol. 1995. PMID: 7791758 Free PMC article.
-
Truncated WT1 mutants alter the subnuclear localization of the wild-type protein.Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):11960-4. doi: 10.1073/pnas.92.26.11960. Proc Natl Acad Sci U S A. 1995. PMID: 8618823 Free PMC article.
-
Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma.Am J Pathol. 1995 Feb;146(2):344-56. Am J Pathol. 1995. PMID: 7856747 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials